Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Breast Neoplasms 23Neoplasms 20Multiple Myeloma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Recurrence 11Leukemia, Myeloid, Acute 11Melanoma 10Colorectal Neoplasms 10Carcinoma, Renal Cell 10Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Hematologic Neoplasms 8Thyroid Neoplasms 7Stomach Neoplasms 6Small Cell Lung Carcinoma 6Sarcoma 6Prostatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Colonic Neoplasms 6Uterine Cervical Neoplasms 5Thyroid Cancer, Papillary 5

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × HER2-Positive Primary Breast Cancer × 1 year × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡